Dystonic tremor – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 12 Aug 2026 04:13:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dystonic tremor – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Botulinum Toxin Type A for Arm Tremor in Patients with Dystonia https://clinicaltrials.eu/trial/study-on-botulinum-toxin-type-a-for-arm-tremor-in-patients-with-dystonia/ Mon, 03 Aug 2026 10:26:59 +0000 https://clinicaltrials.eu/trial/study-on-botulinum-toxin-type-a-for-arm-tremor-in-patients-with-dystonia/ This clinical trial is focused on studying the effects of a treatment for dystonic tremor syndrome, a condition that causes involuntary shaking or trembling of the arms. The treatment being tested is called botulinum toxin type A, which is a muscle relaxant that is injected into the affected muscles to help reduce tremors. The specific product used in this study is known as Dysport 300 E.

The purpose of the study is to explore how different factors, such as clinical characteristics and imaging results, affect the effectiveness of botulinum toxin in treating arm tremors associated with dystonia. Participants in the study will receive injections of the treatment and will be monitored to see how their symptoms change over time. The study will also look at various ways to assess the tremors, including using imaging techniques like magnetic resonance imaging (MRI) to better understand the condition.

Throughout the study, researchers will gather information on how the treatment works for different individuals and what factors might influence its success. This information could help improve treatment strategies for people with dystonic tremor syndrome in the future. The study is expected to continue until 2027, with recruitment starting in late 2024.

]]>